Novo Holdings co — leads £230 million Series C financing for OMass Therapeutics
Novo Holdings co-led OMass Therapeutics’ oversubscribed £230 million ($310 million) Series C financing with Bain Capital Life Sciences and Forbion. OMass develops small-molecule therapeutics in endocrinology and immunology. Proceeds will advance OMS1620 through Phase 2 clinical development for congenital adrenal hyperp